search
Back to results

Effects of Gemigliptin Versus Sitagliptin or Glimepiride With Metformin on Glucose Variability(MAGE, Glucose SD) Patients With Type 2 DM(STABLE Study) (STABLE)

Primary Purpose

Type 2 Diabetes Mellitus

Status
Completed
Phase
Phase 4
Locations
Korea, Republic of
Study Type
Interventional
Intervention
Gemigliptin + Metformin / Sitagliptin + Metformin / Glimepiride + Metformin
Sponsored by
LG Life Sciences
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Type 2 Diabetes Mellitus focused on measuring diabetes mellitus

Eligibility Criteria

20 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients with Type 2 Diabetes Mellitus
  • adults aged ≥ 20 and aged ≤ 70 years old
  • Patients who had not taken anti diabetes drug for 8 weeks prior to screening visit with HbA1c ≥ 7.5%
  • All patients give written informed consent
  • Patients applicable to any one of following 3 categories

    1. Patients with surgically induced infertility
    2. Post-menopause woman ≥45 years of age with over 2 years from the last menstruation
    3. Fertile pre-menopause woman or male patients who has consented for use of two or more contraceptive methods at least up to 14 days after final administration of the investigational product to avoid getting pregnant

Exclusion Criteria:

  • Patients with Type 1 Diabetes, Patients with Diabetic Ketoacidosis or Diabetic Coma as well as Pre-coma
  • Patients with Gestational Diabetes Mellitus or with Secondary Diabetes
  • Patients with NYHA Class III, IV Congestive Heart Failure or with Treatment-requiring Arrhythmia
  • Patients with Thyroid Dysfunction whose TSH is out of normal range, requiring medication therapy
  • Patients with pituitary insufficiency or hypoadrenalism
  • Patients whose BMI is less than 20 Kg/m2 or exceeds 40 Kg/m2
  • Patients whose Total Bilirubin level is 1.5 times higher than the upper limit of normal range and ALT/AST are > 2.5 times higher than the upper limit of normal range
  • Patients currently taking strong CYP3A4 inducers
  • Patients currently taking Warfarin, Dicoumar or Digoxin
  • Patients currently taking any medication from within 4 weeks before Visit 1 (screening) likely to have significant effects on glycemic control or who require to take such medication
  • Patients who had taken anti-obesity drugs within 12 weeks in prior to Visit 1 (screening)
  • Subject who had been treated with Insulin or GLP-1 analogue within 6 months before Visit 1 (screening)
  • Patients who had participated in other clinical study in the past 3 months before Visit 1 (screening)
  • Any other patients whom the investigator considers as inadequate for this study

Sites / Locations

  • Severance hospital

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Active Comparator

Active Comparator

Arm Label

Gemigliptin + Metformin

Sitagliptin + Metformin

Glimepiride + Metformin

Arm Description

Gemigliptin 50 mg + Metformin 500 mg to 1000mg for 12 weeks

Sitagliptin 100 mg + Metformin 500 mg to 1000mg for 12 weeks

Glimepiride 2 mg + Metformin 500 mg to 1000mg for 12 weeks

Outcomes

Primary Outcome Measures

Mean Amplitude Glycemic Excursion

Secondary Outcome Measures

Glucagon
Active GLP-1
CRP
Nitrotyrosine
Glycated albumin
Fructosamine
Glucose Standard Deviation in CGMS data

Full Information

First Posted
May 24, 2013
Last Updated
March 12, 2015
Sponsor
LG Life Sciences
search

1. Study Identification

Unique Protocol Identification Number
NCT01890629
Brief Title
Effects of Gemigliptin Versus Sitagliptin or Glimepiride With Metformin on Glucose Variability(MAGE, Glucose SD) Patients With Type 2 DM(STABLE Study)
Acronym
STABLE
Official Title
A Multicenter, Randomized, Active-controlled, Parallel Group, Open-label, Exploratory Study to Evaluate the Efficacy on Glucose Variability(MAGE, Glucose SD) and Safety of Initial Combination Therapy of Gemigliptin 50mg q.d., Versus Sitagliptin 100mg q.d., or Glimepiride 2mg q.d. With Metformin 500-1,000mg q.d. in Patients With Type 2 Diabetes
Study Type
Interventional

2. Study Status

Record Verification Date
March 2015
Overall Recruitment Status
Completed
Study Start Date
May 2013 (undefined)
Primary Completion Date
August 2014 (Actual)
Study Completion Date
August 2014 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
LG Life Sciences

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
To compare efficacy and safety of initial combination therapy of Gemigliptin versus Sitagliptin or Glimepiride with Metformin on Glucose Variability(MAGE, Glucose SD) in Patients With Type 2 Diabetes Mellitus.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes Mellitus
Keywords
diabetes mellitus

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
69 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Gemigliptin + Metformin
Arm Type
Experimental
Arm Description
Gemigliptin 50 mg + Metformin 500 mg to 1000mg for 12 weeks
Arm Title
Sitagliptin + Metformin
Arm Type
Active Comparator
Arm Description
Sitagliptin 100 mg + Metformin 500 mg to 1000mg for 12 weeks
Arm Title
Glimepiride + Metformin
Arm Type
Active Comparator
Arm Description
Glimepiride 2 mg + Metformin 500 mg to 1000mg for 12 weeks
Intervention Type
Drug
Intervention Name(s)
Gemigliptin + Metformin / Sitagliptin + Metformin / Glimepiride + Metformin
Primary Outcome Measure Information:
Title
Mean Amplitude Glycemic Excursion
Time Frame
Change of MAGE at Week 12 from baseline
Secondary Outcome Measure Information:
Title
Glucagon
Time Frame
Change of Glucagon at Week 12 from baseline
Title
Active GLP-1
Time Frame
Change of Active GLP-1 at Week 12 from baseline
Title
CRP
Time Frame
Change of CRP at Week 12 from baseline
Title
Nitrotyrosine
Time Frame
Change of nitrotyrosine at Week 12 from baseline
Title
Glycated albumin
Time Frame
Change of glycated albumin at Week 4 from baseline
Title
Fructosamine
Time Frame
Change of fructosamine at Week 4 from baseline
Title
Glucose Standard Deviation in CGMS data
Time Frame
Change of Glucose SD at Week 12 from baseline

10. Eligibility

Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients with Type 2 Diabetes Mellitus adults aged ≥ 20 and aged ≤ 70 years old Patients who had not taken anti diabetes drug for 8 weeks prior to screening visit with HbA1c ≥ 7.5% All patients give written informed consent Patients applicable to any one of following 3 categories Patients with surgically induced infertility Post-menopause woman ≥45 years of age with over 2 years from the last menstruation Fertile pre-menopause woman or male patients who has consented for use of two or more contraceptive methods at least up to 14 days after final administration of the investigational product to avoid getting pregnant Exclusion Criteria: Patients with Type 1 Diabetes, Patients with Diabetic Ketoacidosis or Diabetic Coma as well as Pre-coma Patients with Gestational Diabetes Mellitus or with Secondary Diabetes Patients with NYHA Class III, IV Congestive Heart Failure or with Treatment-requiring Arrhythmia Patients with Thyroid Dysfunction whose TSH is out of normal range, requiring medication therapy Patients with pituitary insufficiency or hypoadrenalism Patients whose BMI is less than 20 Kg/m2 or exceeds 40 Kg/m2 Patients whose Total Bilirubin level is 1.5 times higher than the upper limit of normal range and ALT/AST are > 2.5 times higher than the upper limit of normal range Patients currently taking strong CYP3A4 inducers Patients currently taking Warfarin, Dicoumar or Digoxin Patients currently taking any medication from within 4 weeks before Visit 1 (screening) likely to have significant effects on glycemic control or who require to take such medication Patients who had taken anti-obesity drugs within 12 weeks in prior to Visit 1 (screening) Subject who had been treated with Insulin or GLP-1 analogue within 6 months before Visit 1 (screening) Patients who had participated in other clinical study in the past 3 months before Visit 1 (screening) Any other patients whom the investigator considers as inadequate for this study
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
SE Park
Organizational Affiliation
Kangbuk Samsung Hospital
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
BW Lee
Organizational Affiliation
Severance Hospital
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
JH Jo
Organizational Affiliation
Seoul St. Mary's Hospital
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
JH Kim
Organizational Affiliation
Samsung Medical Center
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
JH Jung
Organizational Affiliation
Asan Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Severance hospital
City
Seoul
ZIP/Postal Code
120-752
Country
Korea, Republic of

12. IPD Sharing Statement

Learn more about this trial

Effects of Gemigliptin Versus Sitagliptin or Glimepiride With Metformin on Glucose Variability(MAGE, Glucose SD) Patients With Type 2 DM(STABLE Study)

We'll reach out to this number within 24 hrs